Literature DB >> 15830539

[Clinical features and outcomes in patients with asymptomatic moyamoya disease--from the results of nation-wide questionnaire survey].

Masaru Yamada1, Kiyotaka Fujii, Masashi Fukui.   

Abstract

After induction of noninvasive diagnostic tools, asymptomatic moyamoya disease is occasionally being diagnosed. However, there is no epidemiological or clinical data concerning this condition because of its rarity. To elucidate clinical features and outcomes in patients with asymptomatic moyamoya disease we conducted a nation-wide questionnaire survey. Questionnaires were sent to 88 neurosurgical institutes in 1994 and we received answers from 66 institutions (75% recovery). Diagnosis of moyamoya disease is based on the guidelines established by the research committee on moyamoya disease of the Ministry of Health and Welfare, Japan. Thirty three asymptomatic moyamoya disease patients were collected (11 male, 22 female) and divided into 2 groups; group 1 defined as patients without any symptoms, and group 2 as patients who did not show any symptoms except headache. 80% of group 1 patients were adults, whereas in group 2, children and adults were equally distributed. Follow-up periods were 3 years and 8 months on average. Among conservatively treated 28 patients, 2 patients died from suspected bleeding (mortality 7%) and 4 patients with TIAs resulted in good outcome. Among surgically treated 5 patients, 1 patient showed poor outcome due to post-operative infarction. Other 26 patients showed excellent outcome. Natural course of asymptomatic moyamoya disease seemed benign, but mortality from bleeding is not negligible. A prospective study of asymptomatic moyamoya disease is necessary to clarify its natural course and appropriate management strategy.

Entities:  

Mesh:

Year:  2005        PMID: 15830539

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  5 in total

1.  Early surgical treatment benefits early staged pediatric moyamoya disease--single case report.

Authors:  Go Matsuoka; Yasuo Aihara; Koji Yamaguchi; Tatsuya Ishikawa; Akitsugu Kawashima; Takakazu Kawamata; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2015-04-23       Impact factor: 1.475

2.  Long-Delay Arterial Spin Labeling Provides More Accurate Cerebral Blood Flow Measurements in Moyamoya Patients: A Simultaneous Positron Emission Tomography/MRI Study.

Authors:  Audrey P Fan; Jia Guo; Mohammad M Khalighi; Praveen K Gulaka; Bin Shen; Jun Hyung Park; Harsh Gandhi; Dawn Holley; Omar Rutledge; Prachi Singh; Tom Haywood; Gary K Steinberg; Frederick T Chin; Greg Zaharchuk
Journal:  Stroke       Date:  2017-08-01       Impact factor: 7.914

Review 3.  Moyamoya Biomarkers.

Authors:  Edward R Smith
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 4.  Asymptomatic moyamoya disease: literature review and ongoing AMORE study.

Authors:  Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

5.  Prospective screening of family members with moyamoya disease patients.

Authors:  Cong Han; Hui Feng; Yi-Qin Han; Wei-Wei Liu; Zheng-Shan Zhang; Wei-Zhong Yang; Lian Duan
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.